CNN TürkTaşan derede sürüklenen koyunları çoban kurtardıThe Jerusalem PostPro-Israel advocate kicked to the ground during a pro-Palestinian protest in BerlinPunchHow Nigeria can shape global narrative – Ex-UN officialZDF heuteEntdecken Sie das ZDF-Nachrichtenstudio매일경제“8000억 담았는데 하룻밤 14% 폭락?”…떨어지는 칼날 잡은 서학개미Daily MailPioneering treatment fixes hearts as patients remain awakeLa NaciónAbierto de Palermo: La Natividad-La Dolfina venció a La Ensenada y está invicto en 22 funcionesLenta.ruЛитва ответила на новость о запуске страной подозрительного объекта в сторону РоссииTimes of IndiaOhio shooting: 3 killed, 1 injured at event venue; two suspects in custodyCBS NewsTrump says he wants "permanent" deal with IranGlobal NewsRinzel’s rise lifts him into ‘Hawks history books自由時報歡迎ARMY來高雄 陳其邁PO圖導覽高雄吃喝玩樂
The Daily Newsstand · Free, Always
Sunday, November 22, 2026

How a retracted UK Covid-19 vaccine study tainted the global hunt for mutation-proof shots

Translate

A 2022 study exploring a vaccine design for pan-Sars-CoV-2 immunity was retracted last month after its lead author, then in Britain, admitted to fabricating data and falsifying images in the paper.

While the retraction of the study, widely cited up until this year by international scientists, marks a significant blow to vaccine research, virologists said the foundational science targeting broader coronavirus immunity remained robust and independent of the retracted study.

Citation records show the paper has been downloaded 37,000 times and cited 85 times since its publication, including in eight papers this year.

The papers that cited this study were written by researchers from institutions around the world, such as China, the United States, Australia, Britain, Germany, France, Belgium, Singapore, India and Uganda.

The retracted study, titled “Sars-CoV-2 S2-targeted vaccination elicits broadly neutralising antibodies”, tested a DNA vaccine in mice. It targeted the S2 subunit of the coronavirus, which mutates far less than the rest of the spike protein, to elicit antibodies against diverse variants and coronaviruses that primarily infect mammals and humans.

It was published in July 2022 in the journal Science Translational Medicine by a team led by researchers at the Francis Crick Institute in London.

The biomedical research institute, with more than 2,000 staff and students, was established by six leading organisations in the field, namely Cancer Research UK, the Medical Research Council, the Wellcome Trust, University College London, Imperial College London and King’s College London.

Last month, the journal retracted the article following an investigation by the institute, which concluded that fabricated data and falsified images were present in three figures in the paper.

“The investigation concluded that the first author, Kevin W. Ng, was responsible for this, and he has admitted responsibility,” according to the retraction notice.

“The existence of data fabrication casts doubt on some other experiments presented in the paper, for which primary data and samples are unavailable, precluding post hoc verification,” it added.

01:21

What’s behind the recent spike of Covid-19 cases in China?

The incident is the second retraction this year for Ng, a former PhD student at the Francis Crick Institute. The first one was a separate paper on lung cancer immunotherapy published in the journal Nature in 2023.

“The Francis Crick Institute’s investigation found that co-first author Kevin Ng was responsible for these analyses”, which contained manipulated data and unverifiable source data, according to the retraction notice in January.

According to online information from scientific societies about Ng, he obtained his bachelor’s degree in microbiology and immunology from the University of British Columbia in Vancouver, Canada.

In 2017, he went on to the Francis Crick Institute for PhD studies. He then joined Rockefeller University in New York as a postdoctoral fellow.

An archived version of Ng’s website shows it previously mentioned his PhD in biology and his research experience on “viral infections, cancer and genetics,” though these details had been removed. The current version shows that he writes about music and culture.

Although the paper generated substantial academic interest, molecular virologist Vinod Balasubramaniam said its retraction should not be conflated with the proven real-world effectiveness of authorised vaccines protecting against Covid-19.

Vinod, leader of the Infection and Immunity Research Strength at Monash University Malaysia, said “this retraction does not invalidate the premise that the more conserved S2 subunit of spike is a rational target for broader coronavirus immunity”.

“That idea did not begin with this paper, and it does not depend on it,” Vinod, also an associate professor at the Jeffrey Cheah School of Medicine and Health Sciences, said.

The S2 subunit is a highly conserved region of Sars-CoV-2 spike across emerging variants.

“Most of the mutations that have helped Sars-CoV-2 variants evade vaccine-induced antibodies sit in S1, particularly in the receptor-binding domain. S2 changes more slowly. That is a property of the virus, not a finding unique to one study,” Vinod said.

Laboratories around the world have isolated broadly neutralising monoclonal antibodies targeting conserved sites in S2, while studies in 2024 and 2025 by various research groups have continued to show cross-neutralising responses in mice using independently designed immunogens, he said.

When assessing the broader scientific fallout, Vinod said he was “not aware of any clinical trial or late-stage programme designed solely on the data in this paper”.

“A citation count of this size is not, by itself, evidence of a research collapse,” he said, noting that many citations referenced the broader concept of targeting S2, rather than relying exclusively on the retracted study’s data points.

He added that the retracted work was a preclinical mouse study that used a DNA vaccine and independent groups have been developing their own S2 immunogens, with their own constructs, assays and animal models.

Nevertheless, he said any research group that relied directly on the unreproducible figures should re-examine those conclusions, describing the retraction as “a setback for this study, not a reason to scrap the wider S2 field”.

Addressing potential public confusion regarding authorised vaccines, he stressed that the difference between a preclinical paper and licensed vaccines was significant.

“This paper was never part of the evidence base for any authorised Covid-19 vaccine,” he said. “Licensed vaccines were approved on the basis of large phase 3 clinical trials of full-length spike immunogens, and independent real-world studies have since confirmed their value.”

When asked about the future vaccines, he said the realistic goal in the next five to 10 years was broader, more durable protection against sarbecoviruses, which include Sars-CoV and Sars-CoV-2, than repeatedly updating S1-focused spike vaccines.

He added that this could potentially extend to a wider set of betacoronaviruses, including the virus that causes Middle East respiratory syndrome and other seasonal human coronaviruses, in addition to Sars-CoV and Sars-CoV-2.

He pointed to several strategies being explored by scientists worldwide, such as mosaic approaches that display receptor-binding domains from several sarbecoviruses on a nanoparticle, better engineered immunogens, vaccines built around conserved targets and mucosal or intranasal delivery for immunity at the infection site.

“The most viable path is likely a combination of these, not one magic construct. Authorised, updated spike vaccines remain the proven tool we have today, while these next-generation approaches move, carefully, through the clinic,” he said.

View the original on SCMP China →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.